NVO vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 16, 2026
NVO
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | NVO | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 11.8343 | 9.7656 | GSK |
| PEG Ratio | 4.3209 | 6.1023 | NVO |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2.1% | 5.3% | GSK |
| Earnings Growth | -20.6% | -69.5% | NVO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 60.9/100 | 42.3/100 | NVO |
| Profit Margin | 35.4% | 14.5% | NVO |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | HOLD | NVO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
NVO
MarkdownPrice below a falling SMA50 (slope -8.5%), weak momentum, RSI 44
GSK
NeutralMixed signals - no dominant trend phase, RSI 59
Fundamentals Snapshot
| Metric | NVO | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 1.7 | 10.3 |
| Trailing P/E | 9.5 | 16.2 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | 0.8% | 0.7% |
| Operating Margin | 0.4% | 0.3% |
| EPS | 4.13 | 3.17 |
| Dividend Yield | 0.05% | 0.04% |